BidaskClub downgraded shares of Inogen (NASDAQ:INGN) from a sell rating to a strong sell rating in a research report report published on Friday.

Several other analysts have also recently commented on the company. ValuEngine cut Inogen from a buy rating to a hold rating in a research report on Wednesday, November 7th. Needham & Company LLC reissued a buy rating and set a $280.00 price objective (down previously from $296.00) on shares of Inogen in a research report on Wednesday, November 7th. Zacks Investment Research raised Inogen from a hold rating to a buy rating and set a $290.00 price objective for the company in a research report on Thursday, September 27th. Piper Jaffray Companies lifted their price objective on Inogen from $245.00 to $290.00 and gave the company an overweight rating in a research report on Wednesday, September 12th. Finally, Stifel Nicolaus set a $258.00 price objective on Inogen and gave the company a buy rating in a research report on Tuesday, August 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $244.67.

Shares of Inogen stock opened at $141.75 on Friday. The firm has a market capitalization of $3.03 billion, a PE ratio of 108.21, a price-to-earnings-growth ratio of 2.76 and a beta of 1.56. Inogen has a 12 month low of $112.78 and a 12 month high of $287.79.

Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, November 6th. The medical technology company reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.21. The business had revenue of $95.29 million during the quarter, compared to analysts’ expectations of $90.94 million. Inogen had a return on equity of 18.91% and a net margin of 12.28%. Inogen’s revenue was up 38.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.33 earnings per share. Research analysts expect that Inogen will post 2.1 EPS for the current year.

In related news, Director Raymond Huggenberger sold 10,500 shares of Inogen stock in a transaction on Friday, September 14th. The stock was sold at an average price of $282.57, for a total transaction of $2,966,985.00. Following the completion of the sale, the director now owns 8,797 shares of the company’s stock, valued at $2,485,768.29. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Loren L. Mcfarland sold 2,000 shares of Inogen stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $155.24, for a total value of $310,480.00. Following the sale, the director now directly owns 2,989 shares of the company’s stock, valued at approximately $464,012.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,500 shares of company stock valued at $9,008,475. Insiders own 5.29% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC raised its holdings in Inogen by 0.5% during the third quarter. Teachers Advisors LLC now owns 110,967 shares of the medical technology company’s stock valued at $27,089,000 after buying an additional 532 shares in the last quarter. HRT Financial LLC bought a new position in Inogen during the third quarter valued at about $879,000. Wakefield Asset Management LLLP bought a new position in Inogen during the third quarter valued at about $249,000. Advisors Asset Management Inc. raised its holdings in Inogen by 2,634.0% during the third quarter. Advisors Asset Management Inc. now owns 1,285 shares of the medical technology company’s stock valued at $314,000 after buying an additional 1,238 shares in the last quarter. Finally, MetLife Investment Advisors LLC raised its holdings in Inogen by 49.8% during the third quarter. MetLife Investment Advisors LLC now owns 12,039 shares of the medical technology company’s stock valued at $2,939,000 after buying an additional 4,002 shares in the last quarter. Institutional investors own 96.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: Stock Symbol

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.